Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today that management will participate in fireside chats at two upcoming investor conferences:

BofA Securities 2022 Healthcare Conference

Presentation: Tuesday, May 9, 2023 at 8:55 am PDT (11:55 am ET)

RBC Capital Markets Global Healthcare Conference

Fireside chat: Tuesday, May 16, 2023 at 11:30 am ET

The presentations will be webcast live under the Edgewise events page. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection. Replays of the webcasts will be available on Edgewise’s website for a limited time following the conferences.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2I muscular dystrophies, and McArdle’s disease. The Company is also advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005106/en/